Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Steinberg

Urology Chicago, IL Medical Doctor

NPI 1558585307 CMS profile 251671

5841 S Maryland Ave, Mc 6038, Chicago, IL 60637

Open in the dashboard

General payments

$529,494

263 records reported · program years 2019–2025

Research payments

$17,350

Paid to them · 19 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$877,923 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Gary Steinberg of Chicago, IL is reported in the CMS Open Payments database as having received $529,494 across 263 general payments and $17,350 in research payments paid to them. Separately, studies naming them as principal investigator received $877,923 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,413 24
2025 Research $12,550 15
2024 General $11,401 12
2023 General $64,586 28
2023 Research $3,200 1
2022 General $73,377 31
2021 General $51,738 35
2021 Research $330 1
2020 General $112,103 42
2020 Research $1,270 2
2019 General $176,876 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Steinberg
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Gary Steinberg were reported at $39,413. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Gary Steinberg Urology median Middle half National median
2019 $176,876 $480 $147–$1,201 $163
2020 $112,103 $246 $87–$645 $114
2021 $51,738 $358 $111–$1,000 $132
2022 $73,377 $476 $143–$1,263 $149
2023 $64,586 $560 $168–$1,461 $160
2024 $11,401 $563 $170–$1,464 $164
2025 $39,413 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $115,775 43 payments
  2. Urogen Pharma, Inc. $76,383 29 payments
  3. Photocure Inc $52,474 36 payments
  4. Pfizer Inc. $48,882 37 payments
  5. Janssen Research & Development, LLC $40,654 12 payments
  6. Pfizer International LLC $39,000 1 payment
  7. Ferring Pharmaceuticals Inc. $35,309 21 payments
  8. E.R. Squibb & Sons, L.L.C. $16,690 15 payments
  9. Janssen Global Services, LLC $15,561 16 payments
  10. AstraZeneca UK Limited $13,511 4 payments
  11. Other $75,257 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $481,874 135 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,705 6 payments
  3. Honoraria $14,840 4 payments
  4. Food and Beverage $7,301 91 payments
  5. Travel and Lodging $4,774 27 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $82,620 25 payments
  2. Cysview $52,474 36 payments
  3. V937 $13,750 6 payments
  4. PADCEV Oncology $10,893 7 payments
  5. PADCEV Oncology $9,421 6 payments
  6. Oncuria $8,094 1 payment
  7. Trelstar $6,362 2 payments
  8. BALVERSA $5,813 7 payments
  9. TECENTRIQ $5,515 2 payments
  10. IMFINZI $4,761 4 payments
  11. Other $20,396 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $17,350 19 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Urology: 1,053

Drug cost

$173

Median for Urology: $101,464

Branded share of claims

100%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 16 $173

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$62,445

Medicare's payments for the services billed

Medicare patients

78

Average age 76

Services billed

174

18 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 54%
Arthritis 53%
Ischemic heart disease 41%
Cancer 41%
Diabetes 32%
COPD 32%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Padcev
  • PFIZER INC. $2,507
$2,507 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $545
$545 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $57
$57 — —
JELMYTO
  • UROGEN PHARMA, INC. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record